Research Details

Retatrutide Scientific Research Overview Retatrutide, also identified as LY3437943, is an investigational single-molecule agonist of the GIP, GLP-1, and glucagon receptors. Its triple-receptor profile is being investigated for potential effects on appetite-related signaling, glucose metabolism, lipid metabolism, energy expenditure, and body-weight regulation. Published Research Findings In a peer-reviewed Phase 2 study involving adults with obesity, retatrutide produced dose-dependent body-weight reductions. At the highest studied dose, average reduction reached approximately 17.5% at 24 weeks and 24.2% at 48 weeks. The researchers described the reductions as substantial while emphasizing the need for larger and longer studies. In May 2026, Eli Lilly announced Phase 3 topline findings from TRIUMPH-1. Participants assigned to the highest studied dose experienced an average body-weight reduction of 28.3% over 80 weeks, and 45.3% reportedly reached at least 30% weight reduction. These were company-reported topline findings and should be distinguished from a complete peer-reviewed publication. Retatrutide is also being studied in programs involving type 2 diabetes, cardiovascular and renal outcomes, obstructive sleep apnea, osteoarthritis-related pain, and metabolic liver disease. Evidence and Regulatory Context As of July 2026, retatrutide remains investigational and is not FDA approved. FDA states that retatrutide has not been found safe and effective for any condition and cannot lawfully be used in drug compounding under current federal requirements. Research Links Phase 2: Triple-Hormone-Receptor Agonist Retatrutide for Obesity TRIUMPH-1 Phase 3 Topline Results ClinicalTrials.gov Retatrutide Cardiovascular-Outcomes Study Lilly: Current Retatrutide Research and Development Status FDA Information About Retatrutide and Unapproved GLP-1 Products Research Context: Published findings summarized on this page involve controlled studies of the named molecule and, where applicable, regulated or sponsor-manufactured investigational formulations. These findings do not establish the identity, purity, sterility, safety, effectiveness, or regulatory status of the research material offered on this page. This product is sold strictly for lawful laboratory research and is not intended for human or veterinary use.